PMID- 29115304
OWN - NLM
STAT- MEDLINE
DCOM- 20190521
LR  - 20200306
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Linking)
VI  - 15
IP  - 2
DP  - 2018 Feb
TI  - Tumour heterogeneity and resistance to cancer therapies.
PG  - 81-94
LID - 10.1038/nrclinonc.2017.166 [doi]
AB  - Cancer is a dynamic disease. During the course of disease, cancers generally 
      become more heterogeneous. As a result of this heterogeneity, the bulk tumour 
      might include a diverse collection of cells harbouring distinct molecular 
      signatures with differential levels of sensitivity to treatment. This 
      heterogeneity might result in a non-uniform distribution of genetically distinct 
      tumour-cell subpopulations across and within disease sites (spatial 
      heterogeneity) or temporal variations in the molecular makeup of cancer cells 
      (temporal heterogeneity). Heterogeneity provides the fuel for resistance; 
      therefore, an accurate assessment of tumour heterogeneity is essential for the 
      development of effective therapies. Multiregion sequencing, single-cell 
      sequencing, analysis of autopsy samples, and longitudinal analysis of liquid 
      biopsy samples are all emerging technologies with considerable potential to 
      dissect the complex clonal architecture of cancers. In this Review, we discuss 
      the driving forces behind intratumoural heterogeneity and the current approaches 
      used to combat this heterogeneity and its consequences. We also explore how 
      clinical assessments of tumour heterogeneity might facilitate the development of 
      more-effective personalized therapies.
FAU - Dagogo-Jack, Ibiayi
AU  - Dagogo-Jack I
AD  - Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Yawkey 
      7B, Boston, Massachusetts 02114, USA.
FAU - Shaw, Alice T
AU  - Shaw AT
AD  - Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Yawkey 
      7B, Boston, Massachusetts 02114, USA.
LA  - eng
GR  - R01CA164273/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20171108
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
SB  - IM
MH  - Cell Lineage/genetics
MH  - Clonal Evolution/genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - *Genetic Heterogeneity
MH  - Genomic Instability/*genetics
MH  - Humans
MH  - Neoplasms/*genetics/pathology
MH  - Precision Medicine/trends
EDAT- 2017/11/09 06:00
MHDA- 2019/05/22 06:00
CRDT- 2017/11/09 06:00
PHST- 2017/11/09 06:00 [pubmed]
PHST- 2019/05/22 06:00 [medline]
PHST- 2017/11/09 06:00 [entrez]
AID - nrclinonc.2017.166 [pii]
AID - 10.1038/nrclinonc.2017.166 [doi]
PST - ppublish
SO  - Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. doi: 10.1038/nrclinonc.2017.166. Epub 
      2017 Nov 8.